Related Experiment Video
Updated: Oct 11, 2025

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
Published on: May 16, 2020
Intrinsically Fluorescent Oligomeric Cytotoxic Conjugates Toxic for FGFR1-Overproducing Cancers
Natalia Porębska1, Agata Knapik1, Marta Poźniak1
1Faculty of Biotechnology, Department of Protein Engineering, University of Wroclaw, Joliot-Curie 14a, Wroclaw 50-383, Poland.
Abstract:
Fibroblast growth factor receptor 1 (FGFR1) is an integral membrane protein that transmits prolife signals through the plasma membrane. Overexpression of FGFR1 has been reported in various tumor types, and therefore, this receptor constitutes an attractive molecular target for selective anticancer therapies. Here, we present a novel system for generation of intrinsically fluorescent, self-assembling, oligomeric cytotoxic conjugates with high affinity and efficient internalization targeting FGFR1. In our approach, we employed FGF1 as an FGFR1 recognizing molecule and genetically fused it to green fluorescent protein polygons (GFPp), a fluorescent oligomerization scaffold, resulting in a set of GFPp_FGF1 oligomers with largely improved receptor binding. To validate the applicability of using GFPp_FGF1 oligomers as cancer probes and drug carriers in targeted therapy of cancers with aberrant FGFR1, we selected a trimeric variant from generated GFPp_FGF1 oligomers and further engineered it by introducing FGF1-stabilizing mutations and by incorporating the cytotoxic drug monomethyl auristatin E (MMAE) in a site-specific manner. The resulting intrinsically fluorescent, trimeric cytotoxic conjugate 3xGFPp_FGF1E_LPET_MMAE exhibits nanomolar affinity for the receptor and very high stability. Notably, the intrinsic fluorescence of 3xGFPp_FGF1E_LPET_MMAE allows for tracking the cellular transport of the conjugate, demonstrating that 3xGFPp_FGF1E_LPET_MMAE is efficiently and selectively internalized into cells expressing FGFR1. Importantly, we show that 3xGFPp_FGF1E_LPET_MMAE displays very high cytotoxicity against a panel of different cancer cells overproducing FGFR1 while remaining neutral toward cells devoid of FGFR1 expression. Our data implicate that the engineered fluorescent conjugates can be used for imaging and targeted therapy of FGFR1-overproducing cancers.
Insights
Researchers developed novel fluorescent, self-assembling conjugates targeting Fibroblast Growth Factor Receptor 1 (FGFR1) for cancer therapy. These conjugates show high affinity, efficient internalization, and potent cytotoxicity against FGFR1-overexpressing cancer cells.
Area of Science:
- Bioconjugation chemistry
- Molecular oncology
- Drug delivery systems
Background:
- Fibroblast Growth Factor Receptor 1 (FGFR1) overexpression is common in various cancers, making it a promising target for anticancer therapies.
- Developing targeted therapies requires molecules with high affinity and efficient cellular uptake for specific cancer cells.
Purpose of the Study:
- To create intrinsically fluorescent, self-assembling, oligomeric cytotoxic conjugates targeting FGFR1.
- To evaluate the efficacy of these conjugates as imaging agents and drug carriers for FGFR1-overexpressing cancers.
Main Methods:
- Genetically fusing Fibroblast Growth Factor 1 (FGF1) to green fluorescent protein polygons (GFPp) to create GFPp_FGF1 oligomers.
- Engineering a trimeric GFPp_FGF1 variant with FGF1-stabilizing mutations and site-specific incorporation of monomethyl auristatin E (MMAE).
- Assessing the conjugate's affinity, stability, cellular internalization, and cytotoxicity in FGFR1-expressing cancer cells.
Main Results:
- The engineered conjugate, 3xGFPp_FGF1E_LPET_MMAE, demonstrated nanomolar affinity and high stability for FGFR1.
- Intrinsic fluorescence allowed tracking of efficient and selective cellular internalization into FGFR1-expressing cells.
- The conjugate exhibited potent cytotoxicity against FGFR1-overproducing cancer cells while sparing FGFR1-negative cells.
Conclusions:
- Engineered intrinsically fluorescent, self-assembling cytotoxic conjugates are effective for targeting FGFR1.
- These conjugates hold potential for both imaging and targeted therapy of cancers with aberrant FGFR1 expression.

